<!DOCTYPE html>
<html lang="tr"><head>
<script src="kanserin-ozellikleri-1_files/libs/clipboard/clipboard.min.js"></script>
<script src="kanserin-ozellikleri-1_files/libs/quarto-html/tabby.min.js"></script>
<script src="kanserin-ozellikleri-1_files/libs/quarto-html/popper.min.js"></script>
<script src="kanserin-ozellikleri-1_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.340">

  <meta name="author" content="Serdar Balcı">
  <title>Title</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="kanserin-ozellikleri-1_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="kanserin-ozellikleri-1_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="kanserin-ozellikleri-1_files/libs/revealjs/dist/theme/quarto.css" id="theme">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" class="quarto-title-block center">
  <h1 class="title">Title</h1>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Serdar Balcı 
</div>
</div>
</div>

</section>
<section id="hallmarks-of-cancer" class="title-slide slide level1 center">
<h1>Hallmarks of Cancer</h1>

</section>

<section id="kanserin-ayırıcı-özellikleri" class="title-slide slide level1 center">
<h1>Kanserin ayırıcı özellikleri</h1>

</section>

<section id="kanser-nedir" class="title-slide slide level1 center">
<h1>Kanser nedir?</h1>
<p><strong>A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the same excessive manner after cessation of the stimuli which evoked the change</strong></p>
<p><strong>Disorder of cell growth that is triggered by a series of acquired mutations affecting a single cell and its clonal progeny</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-10.jpg" class="r-stretch"></section>

<section id="kanserin-başlıca-özellikleri-1" class="title-slide slide level1 center">
<h1>Kanserin Başlıca Özellikleri-1</h1>

</section>

<section id="dr.-serdar-balci" class="title-slide slide level1 center">
<h1>Dr.&nbsp;Serdar BALCI</h1>
<p><img data-src="img%5CKanserin-Ozellikleri-11.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-12.png"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-13.png"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-14.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-15.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-16.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="img%5CKanserin-Ozellikleri-17.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-18.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="img%5CKanserin-Ozellikleri-19.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-110.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-111.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="img%5CKanserin-Ozellikleri-112.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-113.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-114.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="img%5CKanserin-Ozellikleri-115.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-116.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-117.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="img%5CKanserin-Ozellikleri-118.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-119.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
</section>

<section id="section" class="title-slide slide level1 center">
<h1></h1>
<p><strong>http://www.cellsignal.com/common/content/content.jsp?id=science-pathways</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-120.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="kanserin-başlıca-özellikleri" class="title-slide slide level1 center">
<h1>Kanserin Başlıca Özellikleri</h1>
<p><strong>Proliferasyon sinyalleri bakımından kendi kendine yeterli olmak</strong></p>
<p><strong>Hücre büyümesini inhibe eden sinyaller karşısında duyarsızlık</strong></p>
<p><strong>Apoptozdan kaçış</strong></p>
<p><strong>Sınırsız replikasyon potansiyeli</strong></p>
<p><strong>Sürekli anjiyogenez</strong></p>
<p><strong>Dokuları invaze etme ve dokularda metastaz yapma yeteneği</strong></p>
<p><strong>Genomdaki dengesizlik</strong></p>
<p><strong>Tümörü uyaran inflamasyon</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-121.jpg" class="r-stretch"></section>

<section id="büyüme-sinyalleri-bakimindan-kendi-kendine-yeterli-olmak" class="title-slide slide level1 center">
<h1>BÜYÜME SINYALLERI BAKIMINDAN KENDI KENDINE YETERLI OLMAK</h1>
<p><img data-src="img%5CKanserin-Ozellikleri-122.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-123.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-124.png"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-125.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-126.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-127.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-128.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-129.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-130.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-131.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-132.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-133.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-134.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-135.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-136.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-137.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-138.jpg"></p>
</section>

<section id="büyüme-sinyalleri-bakımından-kendi-kendine-yeterli-olmak" class="title-slide slide level1 center">
<h1>Büyüme sinyalleri bakımından kendi kendine yeterli olmak</h1>
<ul>
<li><strong>Fizyolojik Büyüme</strong>
<ul>
<li><strong>Büyüme faktörü, hücre zarındaki spesifik reseptöre bağlanır</strong></li>
<li><strong>Büyüme faktörü reseptörü geçici ve kısıtlı olarak aktif hale gelir, zarın iç yüzündeki sinyal ileten proteinleri aktive eder</strong></li>
<li><strong>İkincil haberciler ve sinyal ileten bir dizi molekül ile sinyal çekirdeğe iletilir</strong></li>
<li><strong>DNA transkripsiyonunu aktive eden nükleer düzenleyici faktörler uyarılır ve aktif hale gelir</strong></li>
<li><strong>Hücre siklusu başlar ve hücre bölünmesi gerçekleşir</strong></li>
</ul></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-139.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="büyüme-faktörleri" class="title-slide slide level1 center">
<h1>Büyüme Faktörleri</h1>
<ul>
<li><strong>Kanser hücreleri kendilerini uyaracak büyüme faktörleri sentezlerler</strong></li>
<li><strong>Glioblastom</strong>
<ul>
<li><strong>Platelet kökenli büyüme faktörü (PDGF) sentezler</strong></li>
<li><strong>PDGF reseptörü eksprese ederler</strong></li>
</ul></li>
<li><strong>Sarkomlar</strong>
<ul>
<li><strong>Transforming growth factor-α (TGF-α) sentezler</strong></li>
<li><strong>TGF-α reseptör</strong></li>
</ul></li>
<li><strong>Stroma ile ilişkiler</strong>
<ul>
<li><strong>Tümör hücreleri, stromal hücreleri uyaran sinyaller gönderir</strong></li>
<li><strong>Stroma hücreleri de tümörü uyaran büyüme faktörleri sentezler</strong></li>
</ul></li>
</ul>
</section>

<section id="büyüme-faktörü-reseptörleri-ve-reseptör-olmayan-tirozin-kinazlar" class="title-slide slide level1 center">
<h1>Büyüme faktörü reseptörleri ve reseptör olmayan tirozin kinazlar</h1>
<p><strong>Mutant reseptör proteinleri:</strong></p>
<p><strong>Hücreleri sürekli mitoz için uyaran sinyaller üretir</strong></p>
<p><strong>Bu uyarı ortamda büyüme faktörü olmasa da olur</strong></p>
<ul>
<li><strong>Büyüme faktörü reseptörünün aşırı ekspresyonu</strong>
<ul>
<li><strong>Normalde proliferasyonu uyarmayacak düşük dozdaki büyüme faktörüne duyarlı</strong></li>
</ul></li>
<li><strong>ERBB1 (EGF reseptörü)</strong>
<ul>
<li><strong>Akciğer skuamöz hücreli karsinomların %80’inde aşırı ekspresyon</strong></li>
<li><strong>Glioblastomların %50’si</strong></li>
<li><strong>Baş boyun epitelyal tümörlerinin %80-100’ünde</strong></li>
</ul></li>
<li><strong>HER2/NEU (ERBB2)</strong>
<ul>
<li><strong>Meme kanserlerinin %35-30’unda amplifiye</strong></li>
<li><strong>Akciğer, over ve tükrük bezi adenokarsinomlarında</strong></li>
<li><strong>Küçük miktardaki büyüme faktörü ile mitoz uyarılır</strong></li>
<li><strong>Meme kanserinde yüksek miktarda HER2/NEU protein varlığı kötü prognoz</strong></li>
<li><strong>Anti-HER2/NEU antikorlar meme kanseri tedavisinde kullanılıyor</strong></li>
</ul></li>
</ul>
</section>

<section id="ilerleme-yönünde-sinyal-ileten-proteinler" class="title-slide slide level1 center">
<h1>İlerleme yönünde sinyal ileten proteinler</h1>
<ul>
<li><strong>Uyarıyı reseptörden alırlar</strong></li>
<li><strong>Uyarıyı nükleusa taşırlar</strong>
<ul>
<li><strong>İkinci haberciler</strong></li>
<li><strong>Bir dizi fosforilasyon</strong></li>
</ul></li>
<li><strong>Eğer bu uyarılarda otonomi gelişirse, çekirdeğe sürekli uyaran aktarılır</strong></li>
<li><strong>RAS</strong></li>
<li><strong>ABL</strong></li>
</ul>
</section>

<section id="ras-protein" class="title-slide slide level1 center">
<h1>RAS protein</h1>
<ul>
<li><strong>İnsan tümörlerinde en çok mutasyona uğrayan proto-onkogen</strong></li>
<li><strong>Tüm tümörlerin %30’u RAS mutasyonu içerir</strong></li>
<li><strong>Kolon ve pankreas karsinomlarında daha sıktır</strong></li>
<li><strong>G protein</strong>
<ul>
<li><strong>GTP ile fosforile olur</strong></li>
</ul></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-140.png" class="r-stretch"></section>

<section id="ras" class="title-slide slide level1 center">
<h1>RAS</h1>
<ul>
<li><strong>Normal</strong>
<ul>
<li><strong>GTP’ye bağlandığında aktif</strong></li>
<li><strong>GTPase ile inaktif hale döner</strong></li>
<li><strong>GTPase-activating proteins (GAPs)</strong></li>
</ul></li>
<li><strong>Mutasyonda</strong>
<ul>
<li><strong>Defosforile olamaz</strong></li>
<li><strong>Sürekli aktif kalır</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-141.png" class="r-stretch"></section>

<section id="gaps" class="title-slide slide level1 center">
<h1>GAPs</h1>
<ul>
<li><strong>GTPase-activating protein</strong></li>
<li><strong>Neurofibromin-1 (NF-1)</strong>
<ul>
<li><strong>Fonksiyon kaybına neden olan mutasyon olduğunda</strong></li>
<li><strong>RAS aktif kalır</strong></li>
<li><strong>Neurofibromatozis hastalığı gelişir</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-142.png" class="r-stretch"></section>

<section id="raferkmap-kinaz-yolağı" class="title-slide slide level1 center">
<h1>RAF/ERK/MAP kinaz yolağı</h1>
<p><strong>Melanomların %60’ında aktif</strong></p>
<p><strong>BRAF mutasyonu papiller tiroid karsinomlarında görülür</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="abl" class="title-slide slide level1 center">
<h1>ABL</h1>
<ul>
<li><strong>Reseptör ilişkisiz tirozin kinaz</strong></li>
<li><strong>Kronik Myelojenik Lösemi</strong>
<ul>
<li><strong>ABL Chr9’dan Chr22’ye translokasyon olur</strong></li>
<li><strong>BCR ile birleşir</strong></li>
<li><strong>Sürekli aktivasyon</strong></li>
<li><strong>RAS yolağını da aktive der</strong></li>
</ul></li>
<li><strong>Hedefe yönelik tedavilerin ilki</strong>
<ul>
<li><strong>BCR-ABL kinaz inhibitörü (Gleevec)</strong></li>
</ul></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-143.png" class="r-stretch"><p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
</section>

<section id="nükleer-transkripsiyon-faktörleri" class="title-slide slide level1 center">
<h1>Nükleer Transkripsiyon Faktörleri</h1>
<ul>
<li><strong>MYC, MYB, JUN, FOS, ve REL onkogenleri</strong>
<ul>
<li><strong>Büyümeyi uyaran genlerin (Cyclin) ekspresyonlarını düzenlerler</strong></li>
</ul></li>
</ul>
</section>

<section id="myc" class="title-slide slide level1 center">
<h1>MYC</h1>
<ul>
<li><strong>Büyümeyi uyaran Siklin bağımlı kinazları aktive eder (cyclin-dependent kinases, CDKs)</strong></li>
<li><strong>CDK inhibitörlerini (CDKIs) baskılarlar</strong></li>
<li><strong>Aerobik glikolize neden olan genleri aktive ederler (Warburg etkisi)</strong></li>
<li><strong>Glutamin kullanımını arttırırlar</strong></li>
<li><strong>Translokasyon</strong>
<ul>
<li><strong>t(8;14) Burkitt lenfoma</strong></li>
</ul></li>
<li><strong>Amplifikasyon</strong>
<ul>
<li><strong>Meme, kolon, akciğer</strong></li>
<li><strong>Nöroblastom, Akciğer küçük hücreli karsinom (NMYC, LMYC)</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CKanserin-Ozellikleri-144.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-145.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-146.jpg"></p>
</section>

<section id="siklin-ve-siklin-bağımlı-kinazlar" class="title-slide slide level1 center">
<h1>Siklin ve siklin bağımlı kinazlar</h1>
<ul>
<li><strong>Kontrol noktaları</strong></li>
<li><strong>G0 → G1</strong></li>
<li><strong>G1 → S</strong>
<ul>
<li><strong>Kısıtlama noktası</strong></li>
<li><strong>Hız kısıtlayıcı basamak</strong></li>
</ul></li>
</ul>
<p><strong>Kontrol noktaları anormal DNA proliferasyonunu engeller</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-147.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Neoplazilerde CyclinD veya CDK4 ekspresyonları sıktır</strong></li>
<li><strong>Cyclin D</strong>
<ul>
<li><strong>Meme, özefagus, karaciğer, lenfomalar, plazma hücre neoplazileri</strong></li>
</ul></li>
<li><strong>CDK4</strong>
<ul>
<li><strong>Melanomlar, sarkomlar, glioblastomlar</strong></li>
</ul></li>
<li><strong>CDKI</strong>
<ul>
<li><strong>Çoğu malignitede mutasyon veya gen susturulması ile inaktiftir</strong></li>
<li><strong>CDKN2A germ hücre mutasyonunda</strong>
<ul>
<li><strong>%25’inde melanom yatkınlığı</strong></li>
</ul></li>
<li><strong>Somatik akkiz delesyon veya inaktivasyonu</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CKanserin-Ozellikleri-148.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="homework" class="title-slide slide level1 center">
<h1>Homework</h1>
<p><strong>Rous sarcoma virus</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-149.jpg" class="r-stretch"></section>

<section id="büyüme-inhibitörlerine-duyarsizlik" class="title-slide slide level1 center">
<h1>BÜYÜME INHIBITÖRLERINE DUYARSIZLIK</h1>

</section>

<section id="rb-geni-hücre-siklusunun-yöneticisi" class="title-slide slide level1 center">
<h1>RB geni: Hücre siklusunun yöneticisi</h1>
<ul>
<li><strong>13q14</strong></li>
<li><strong>Retinoblastoma hem sporadik hem de ailesel formda benzer şekilde görülür</strong></li>
<li><strong>Ailesel formu otozomal dominanttır</strong></li>
<li><strong>RB geninin homozigot kaybı</strong>
<ul>
<li><strong>Meme kanseri, Küçük hücreli akciğer kanseri ve mesane kanseri</strong></li>
</ul></li>
<li><strong>Retinoblastom hastaları osteosarkom ve yumuşak doku sarkomları için artmış risk taşır</strong></li>
</ul>
</section>

<section id="retinoblastom" class="title-slide slide level1 center">
<h1>Retinoblastom</h1>
<p><img data-src="img%5CKanserin-Ozellikleri-150.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-151.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-152.jpg"></p>
<p><img data-src="img%5CKanserin-Ozellikleri-153.jpg"></p>
<p><strong>Figure 2, from Pediatr Radiol. Jun 2012; 42(6): 738–749. PMCID: PMC3530407</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-154.jpg"></p>
<p><strong>Figure 7.4b </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
</section>

<section id="knudson-çift-darbe-hipotezi" class="title-slide slide level1 center">
<h1>Knudson çift darbe hipotezi</h1>
<p><img data-src="img%5CKanserin-Ozellikleri-155.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-156.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="sadece-bir-rb-geni-mutant-ise-hücre-neoplastik-olur-mu" class="title-slide slide level1 center">
<h1>Sadece bir Rb geni mutant ise hücre neoplastik olur mu?</h1>
<p><strong>Hayır</strong></p>
<p><strong>Tümör Baskılayıcı Genlerin her iki alleli de kaybolursa neoplazi gelişir</strong></p>
<p><strong>Bir genin fonksiyonunun kaybı hangi mekanizmalar ile olur?</strong></p>
<p><strong>Proto-onkogenin tek alleli mutasyona uğrarsa neoplazi gelişir mi?</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-157.png"></p>
<p><strong>G1 kontrol noktası</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-158.png"></p>
<p><strong>G1 kontrol noktası</strong></p>
<p><strong>cyclin E transkripsiyonu</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-159.png"></p>
<p><strong>G1 kontrol noktası</strong></p>
<p><strong>HPV E7 protein mimics here</strong></p>
<p><strong>cyclin E transkripsiyonu</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="tp53-geni-genomun-koruyucusu" class="title-slide slide level1 center">
<h1>TP53 GeniGenomun Koruyucusu</h1>
<ul>
<li><strong>Sessizlik</strong>
<ul>
<li><strong>Geçici olarak hücre siklusunun durdurulması</strong></li>
</ul></li>
<li><strong>Yaşlılık</strong>
<ul>
<li><strong>Kalıcı hücre siklus durdurulması</strong></li>
</ul></li>
<li><strong>Apoptoz</strong>
<ul>
<li><strong>Programlanmış hücre ölümünün başlaması</strong></li>
</ul></li>
</ul>
<p><strong>Rb dış uyaranlara, p53 iç uyaranlara cevap verir</strong></p>
</section>

<section id="p53-aktivasyonuna-neden-olanlar" class="title-slide slide level1 center">
<h1>p53 aktivasyonuna neden olanlar</h1>
<p><strong>Anoksi</strong></p>
<p><strong>Uygunsuz onkojenik protein aktivasyonu</strong></p>
<p><strong>DNA bütünlüğünün hasara uğraması</strong></p>
<p><strong>p53 bir DNA hasar cevabı proteinidir</strong></p>
</section>

<section id="p53" class="title-slide slide level1 center">
<h1>p53</h1>
<ul>
<li><strong>Normal</strong>
<ul>
<li><strong>Kısa bir yarı ömrü var</strong></li>
<li><strong>20 dakika içinde MDM2 ile birleşir ve parçalanır</strong></li>
</ul></li>
<li><strong>Stres durumunda</strong>
<ul>
<li><strong>Protein kinazlar aktive olur</strong>
<ul>
<li><strong>ATM (ataxia telangiectasia mutated)</strong></li>
</ul></li>
<li><strong>P53’te post-transkripsiyon değişikliklere neden olur</strong></li>
<li><strong>P53 MDM2’den ayrılır</strong></li>
<li><strong>p53 aktivitesi devam eder</strong></li>
</ul></li>
<li><strong>Tamir sonrası</strong>
<ul>
<li><strong>P53, MDM2 ekspresyonunu uyarır, p53 normal seviyelere döner ve hücre siklusu devam eder</strong></li>
</ul></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-160.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="p53-kontrolünde-hücre-siklusunda-durma" class="title-slide slide level1 center">
<h1>p53 kontrolünde hücre siklusunda durma</h1>
<p><strong>P53, CDKI ekspresyonunu sağlar: CDKN1A (p21)</strong></p>
<p><strong>p21 protein, cyclin–CDK complekslerini inhibe eder</strong></p>
<p><strong>Rb fosforilasyonunu engeller</strong></p>
<p><strong>G1 fazında hücre siklusu durur</strong></p>
<p><strong>DNA hasarını tamir etmeye vakit kalır</strong></p>
</section>

<section id="p53-nedenli-yaşlılık-senescence" class="title-slide slide level1 center">
<h1>p53 nedenli yaşlılık (senescence)</h1>
<p><strong>Global kromatin değişiklikleri</strong></p>
<p><strong>Gen ekspresyonu kalıcı olarak durur</strong></p>
<p><strong>Hücre siklusunda kalıcı blok oluşur</strong></p>
</section>

<section id="p53-nedenli-apoptoz" class="title-slide slide level1 center">
<h1>p53 nedenli apoptoz</h1>
<p><strong>Kalıcı DNA hasarı</strong></p>
<p><strong>Pro-apoptotik genler (BAX ve PUMA) aktif olur</strong></p>
</section>

<section id="p53-1" class="title-slide slide level1 center">
<h1>p53</h1>
<ul>
<li><strong>Kanserlerin %70’inde p53’ün her iki allelinde kayıp vardır</strong></li>
<li><strong>Diğerlerinde TP53’ün üst ve altındaki yolaklarda hasar vardır</strong></li>
<li><strong>p53 onkojenik DNA virüsleri ile inhibe olur</strong>
<ul>
<li><strong>Hepatit B</strong></li>
<li><strong>EBV</strong></li>
</ul></li>
</ul>
</section>

<section id="li-fraumeni-sendromu" class="title-slide slide level1 center">
<h1>Li-Fraumeni sendromu</h1>
<p><strong>Mutant TP53 alleli kalıtılır</strong></p>
<p><strong>50 yaş civarında kanser riskinde 25x artış</strong></p>
<p><strong>Sarkomlar, meme kanseri, lösemi, beyin tümörleri, adrenal corteks karsinomları</strong></p>
<p><strong>Genç yaşta</strong></p>
<p><strong>Çok sayıda primer tümör</strong></p>
</section>

<section id="transforming-growth-factor-β-yolağı" class="title-slide slide level1 center">
<h1>Transforming Growth Factor-β Yolağı</h1>
<ul>
<li><strong>Proliferasyonun belirgin inhibitörü</strong></li>
<li><strong>TGF-β Reseptör I ve II</strong>
<ul>
<li><strong>Dimerizasyon ile aktive olur</strong></li>
</ul></li>
<li><strong>Büyüme engelleyici aktivite</strong>
<ul>
<li><strong>CDKI transkripsiyonunu</strong></li>
</ul></li>
<li><strong>Büyümeyi uyaran genlerin baskılanması</strong>
<ul>
<li><strong>MYC, CDK2, CDK4</strong></li>
<li><strong>Cyclin A ve E</strong></li>
</ul></li>
<li><strong>SMAD molekülleri</strong>
<ul>
<li><strong>Antiproliferatif sinyalleri reseptörden nükleusa taşır</strong></li>
</ul></li>
<li><strong>TGF-β sinyali ile epitelyal-mezenkimal dönüşüm aktive olur</strong></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-161.jpg" class="r-stretch"><p><strong>Figure 5.21 </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
</section>

<section id="transforming-growth-factor-β-yolağındaki-değişiklikler" class="title-slide slide level1 center">
<h1>Transforming Growth Factor-β Yolağındaki değişiklikler</h1>
<ul>
<li><strong>Mutasyonlar</strong>
<ul>
<li><strong>TGF-β reseptör tip II</strong>
<ul>
<li><strong>Kolon, mide, endometrium kanserleri</strong></li>
</ul></li>
<li><strong>SMAD molekülü</strong>
<ul>
<li><strong>SMAD4, pankreas kanserleri</strong></li>
</ul></li>
</ul></li>
<li><strong>Pankreas kanserlerinin %100’ünde, kolon kanserlerinin %83’ünde TGF-β yolağında bir mutasyon vardır</strong></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-162.jpg" class="r-stretch"><p><strong>Figure 6.29d </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
</section>

<section id="kontakt-inhibisyon" class="title-slide slide level1 center">
<h1>Kontakt inhibisyon</h1>
<ul>
<li><strong>Normal hücreler kültürde büyütüldüklerinde</strong>
<ul>
<li><strong>Büyüme tek bir tabaka oluşana kadar devam eder</strong></li>
<li><strong>Hücre- hücre bağlantıları nedeniyle bundan sonra bölünme durur</strong></li>
</ul></li>
<li><strong>Kanser hücrelerinde</strong>
<ul>
<li><strong>Kontakt inhibisyon yoktur</strong></li>
<li><strong>Hücreler büyümeye devam eder, birbiri üzerine birikmeye devam eder</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CKanserin-Ozellikleri-163.png"></p>
<p><strong>Figure 3.7 from The Biology Of Cancer (2007) - Weinberg</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-164.jpg"></p>
<p><strong>Figure 3.7a </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
<p><img data-src="img%5CKanserin-Ozellikleri-165.jpg"></p>
<p><strong>Figure 3.12 </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
<p><img data-src="img%5CKanserin-Ozellikleri-166.png"></p>
<p><strong>Figure 3.7 from The Biology Of Cancer (2007) - Weinberg</strong></p>
</section>

<section id="e-cadherin" class="title-slide slide level1 center">
<h1>E-cadherin</h1>
<ul>
<li><strong>E-cadherin epitelyal hücrelerdeki hücre-hücre bağlantılarını sağlar</strong></li>
<li><strong>Tümör supresör gen olan NF2 (neurofibromin-2, merlin), E-cadherin bağımlı kontakt inhibisyonu aktive eder</strong></li>
<li><strong>NF2’nin homozigot kaybında → nöral tümörler gelişir</strong>
<ul>
<li><strong>Nörofibromatozis</strong></li>
</ul></li>
<li><strong>E-cadherin, APC tarafından da düzenlenir (adenomatous polyposis coli geni)</strong></li>
</ul>
<p><strong>APC yok</strong></p>
<p><strong>β-Catenin WNT durumdan bağımsız olarak çekirdeğe geçer</strong></p>
<p><strong>WNT sinyali APC’yi baskılar</strong></p>
<p><strong>β-Catenin çekirdeğe geçer</strong></p>
<p><strong>APC aktif</strong></p>
<p><strong>β-Catenin yıkılır</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-167.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>β-Catenin çekirdekte aktiftir</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-168.png"></p>
<p><strong>Proliferasyon için cyclin D1 ve MYC transkripsiyonu olur</strong></p>
<p><strong>TWIST ve SLUG eksprese edilir</strong></p>
<p><strong>Bunlar E-cadherin ekspresyonunu baskılar</strong></p>
<p><strong>Kontakt inhibisyon azalır</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="adenomatous-polyposis-coli" class="title-slide slide level1 center">
<h1>Adenomatous Polyposis Coli</h1>
<ul>
<li><strong>APC bir tümör baskılayıcı gendir</strong></li>
<li><strong>Tek alleldeki mutasyonda</strong>
<ul>
<li><strong>20 yaş civarında</strong></li>
<li><strong>Kolonda yüzlerce, binlerce adenomatöz polip gelişir</strong></li>
</ul></li>
<li><strong>Diğer allel de mutasyona uğrarsa</strong>
<ul>
<li><strong>Malignite gelişir</strong></li>
</ul></li>
<li><strong>APC mutasyonları sporadik kolon tümörlerinin %70-80’inde görülür</strong></li>
<li><strong>Normal APC geni olan kolon kanserlerinde β-catenin aktive edici mutasyonları görülür</strong>
<ul>
<li><strong>APC’nin yıkım etkisine direnç gösterecek şekilde mutasyonlar olur</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CKanserin-Ozellikleri-169.jpg"></p>
<p><strong>Figure 7.22 </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
<p><img data-src="img%5CKanserin-Ozellikleri-170.jpg"></p>
<p><strong>Figure 7.24a </strong> _ The Biology of Cancer_ __ (© Garland Science 2007)__</p>
<p><img data-src="img%5CKanserin-Ozellikleri-171.jpg"></p>
</section>

<section id="hücre-ölümünden-kaçiş" class="title-slide slide level1 center">
<h1>HÜCRE ÖLÜMÜNDEN KAÇIŞ</h1>

<img data-src="img%5CKanserin-Ozellikleri-172.png" class="r-stretch"></section>

<section id="dış-yolak" class="title-slide slide level1 center">
<h1>Dış yolak</h1>
<p><strong>TNF reseptörü CD95 (Fas) ligandı olan CD95L’a bağlanır</strong></p>
<p><strong>Reseptörde trimerizasyon ve ölüm grubu ile bağlanma</strong></p>
<p><strong>FADD bağlanamsı</strong></p>
<p><strong>Procaspase-8 küçük fragmanalra bölünerek aktive olur</strong></p>
<p><strong>Caspase-8 yolağındaki caspase-3’ü aktive eder</strong></p>
<p><strong>DNA ve diğer yapılar yıkılır</strong></p>
<p><strong>Hücre ölümü</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>

<img data-src="img%5CKanserin-Ozellikleri-173.png" class="r-stretch"></section>

<section id="iç-yolak" class="title-slide slide level1 center">
<h1>İç yolak</h1>
<p><strong>Büyüme faktörlerinin kaybı, stres, hasar</strong></p>
<p><strong>Mitokondri dış membranında geçirgenlik artışı</strong></p>
<p><strong>Cytochrome c sitozole çıkar</strong></p>
<p><strong>APAF-1’e bağlanır</strong></p>
<p><strong>caspase-9’u aktive eder</strong></p>
<p><strong>Diğer kaspazlar aktive edilir</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="intrinsic-yolak-iç-yolak" class="title-slide slide level1 center">
<h1>Intrinsic Yolak (İç yolak)</h1>
<ul>
<li><strong>Pro-apoptotik proteinler</strong>
<ul>
<li><strong>BAX ve BAK</strong></li>
<li><strong>Mitokondri geçirgenliğini direk artırır</strong></li>
</ul></li>
<li><strong>Anti-apoptotik proteinler</strong>
<ul>
<li><strong>BCL2 ve BCL-XL</strong></li>
<li><strong>BAX ve BAK’ı baskılar</strong></li>
</ul></li>
<li><strong>BH3-only proteinleri</strong>
<ul>
<li><strong>BAD, BID ve PUMA</strong></li>
<li><strong>Pro ve enati-apoptotik genlerdeki dengeyi sağlar</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="folliküler-b-hücreli-lenfoma" class="title-slide slide level1 center">
<h1>Folliküler B Hücreli Lenfoma</h1>
<ul>
<li><strong>t(14;18) (q32;q21) translokasyonu</strong></li>
<li><strong>14q32</strong>
<ul>
<li><strong>Ig ağır zincir lokusu</strong></li>
<li><strong>Aktif transkripsiyon sahası</strong></li>
</ul></li>
<li><strong>18q21</strong>
<ul>
<li><strong>BCL2</strong></li>
</ul></li>
<li><strong>Yanyana geldiklerinde</strong>
<ul>
<li><strong>BCL2 fazla eksprese olur</strong></li>
</ul></li>
<li><strong>B hücreleri apoptoza gidemez</strong></li>
<li><strong>Yavaş seyirli tümörlerdendir</strong>
<ul>
<li><strong>Aktif proliferasyona neden olan bir mutasyon değil, ölümü engelleyen bir mutasyon olduğu için</strong></li>
</ul></li>
</ul>
</section>

<section id="otofaji" class="title-slide slide level1 center">
<h1>Otofaji</h1>
<ul>
<li><strong>Stres altında hücrenin kendi parçalarını tüketmesi</strong></li>
<li><strong>Kanser hücreleri otofajiye engel olan mutasyonlar oluşturabilir</strong></li>
<li><strong>Kanser hücreleri uygunsuz ortamlarda yaşamak için otofajiyi kullanabilir</strong>
<ul>
<li><strong>Tedavi gibi</strong></li>
</ul></li>
</ul>

<img data-src="img%5CKanserin-Ozellikleri-174.jpg" class="r-stretch"></section>

<section id="sinirsiz-çoğalma-potansiyeli" class="title-slide slide level1 center">
<h1>SINIRSIZ ÇOĞALMA POTANSIYELI</h1>

</section>

<section id="normal-hücrelerde-telomerler-kısalır" class="title-slide slide level1 center">
<h1>Normal hücrelerde telomerler kısalır</h1>

<img data-src="img%5CKanserin-Ozellikleri-175.png" class="r-stretch"><p><strong>Yaklaşık 60, 70 bölünme kapasitesi vardır</strong></p>
<p><strong>Telomerler kısalır</strong></p>
<p><strong>DNA tamir mekanizması DNA çift zincir hasarı olarak algılar</strong></p>
<p><strong>Hücre yaşlılığa girer</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="neoplazide-telomer-kısalması" class="title-slide slide level1 center">
<h1>Neoplazide telomer kısalması</h1>
<p><img data-src="img%5CKanserin-Ozellikleri-176.png"></p>
<p><strong>TP53 ve RB mutasyonlarında hücre çoğalmaya zorlanır</strong></p>
<p><strong>Nonhomolog uç ekleme yapılır</strong></p>
<p><strong>Kromozomların kısa uçları birleştirilir</strong></p>
<p><strong>Disentrik kromozomlar oluşur</strong></p>
<p><strong>Anafazda her iki noktadan çekim olur</strong></p>
<p><strong>Yeni DNA çift zincir kayıpları</strong></p>
<p><strong>Tekrarlayan birleşmeler ve kırıklar</strong></p>
<p><strong>Apoptoza gidebilir</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-177.png"></p>
<p><strong>Rubin’s Pathology 7th Ed</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-178.png"></p>
<ul>
<li><strong>Hemen tüm kanserlerde telomer korunması görülür</strong></li>
<li><strong>Telomeraz enzimi fazla çalışır</strong></li>
<li><strong>Kolon tümörlerinde</strong>
<ul>
<li><strong>Erken lezyonlarda yüksek genomik instabilite, düşük telomeraz aktivitesi</strong></li>
<li><strong>Malignite geliştiğinde, kompleks karyotip ve yüksek telomeraz görülür</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CKanserin-Ozellikleri-179.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<div class="footer footer-default">

</div>
</section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'smaller': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Kopyalandı");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Kopyalandı");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>